- Gilead’s ambition is moving from a predominantly virology focused portfolio to a more diverse one with an emphasis on adding oncology and inflammation asset
- To accomplish this a wide net needed to be deployed to rapidly build a portfolio through external sourcing and internal innovation
- This has resulted in a diverse set of acquisitions, partnerships, opt-ins, and collaborations across program phases and modalities, resulting in a complex manufacturing network
- This talk will cover the strategies being deployed across the pillars of Process Development, Supply Chain, Quality, Regulatory, and External Manufacturing to realize Gilead’s 2030 ambition
—
VP of Biologics Process Development
Gilead Sciences
Art Hewig is the Vice President of Biologics Process Development at Gilead Sciences in Oceanside, CA. He leads a >200-member organization of scientists and engineers to deliver early stage, late stage, and life cycle management assets of Gilead’s diverse, multi-modality biologics portfolio. He has end to end accountability spanning all phases from research collaboration to commercialization, for the cell line, drug substance, drug product and analytical development as well as clinical quality control.
Prior to this role, Dr. Hewig worked at Amgen for 19 years in early and late-stage bioprocess development. He has a proven track record of strategic, empathetic leadership, while delivering to business goals. He is adept at organizational design, with a focus on agility & continuous learning.
Dr. Hewig received his doctorate in Chemical Engineering from Carnegie Mellon University and BS/MS in Chemical Engineering from Rensselaer Polytechnic Institute.
